EPIK Biosciences

EPIK Biosciences is a psychedelic drug development company focused on building a portfolio of proprietary ketamine- and dextromethorphan (DXM)-based combination therapies. Founded in 2026 and based in Austin, Texas, the company leverages a proprietary platform rooted in NMDA receptor modulation to engineer synergistic co-delivery formulations. These therapies target mental health disorders (such as depression, anxiety, and PTSD), severe and chronic pain, and substance use disorders. By utilizing already FDA-approved, non-Schedule I compounds, EPIK aims to establish a lower-risk, expedited regulatory pathway (such as 505(b)(2)) for patient-friendly, at-home delivery formats like sublingual films, lozenges, and topical applications.